Neurofilament light chain as a marker for neuronal damage: integrating in vitro studies and clinical findings in patients with oxaliplatin-induced neuropathy
Summary
Both in vitro and clinical data indicate that oxaliplatin exposure results in elevated NfL levels. Further prospective studies are needed to evaluate NfL as an early biomarker for OIPN, specifically focusing on the timing of blood sampling during chemotherapy treatment to enable the timely reduction of oxaliplatin. © 2025. The Author(s).
| Authors | Gehr NL, Mortensen C, Stage TB, Pedersen MRV, Rafaelsen SR, Madsen JS, Olsen DA, Timm S, Jensen LH, Hansen TF, Finnerup NB, Ventzel L |
|---|---|
| Journal | Cancer chemotherapy and pharmacology |
| Publication Date | 2025 Apr 10;95(1):53 |
| PubMed | 40208334 |
| PubMed Central | PMC11985616 |
| DOI | 10.1007/s00280-025-04773-w |